How long does it take to see obvious therapeutic effects after taking erlotinib?

When Erlotinib (Erlotinib) is used to treat non-small cell lung cancer and pancreatic cancer , the onset of effect varies depending on individual patient differences, tumor burden, EGFR mutation status, and treatment combination regimens.

Generally speaking, in patients with EGFR mutation-positive non-small cell lung cancer, erlotinib has a relatively rapid onset of action, and most patients can observe signs of tumor shrinkage or disease stabilization through imaging evaluation within 4 to 8 weeks after starting treatment. Some patients even experience symptom relief within 2 to 4 weeks, such as significant improvement in cough, dyspnea, chest pain and other symptoms. Imaging follow-up is usually recommended for the first time 6 to 8 weeks after starting erlotinib therapy to assess response and decide whether to continue the current treatment regimen.

For pancreatic cancer patients treated with gemcitabine, the efficacy evaluation period of erlotinib is slightly longer. It generally takes 8 to 12 weeks to initially judge the treatment response. The changes in tumor volume, the decrease in the level of tumor marker CA19-9, and the improvement of clinical symptoms are mainly observed. It is worth noting that some patients may experience side effects such as rash and diarrhea in the early stages of treatment. These reactions are also considered to be related to the biological activity of the drug to some extent. Some studies have pointed out that the occurrence of skin reactions is positively correlated with the efficacy.

It needs to be emphasized that the evaluation of the efficacy of erlotinib should comprehensively consider changes in imaging, clinical symptoms and biochemical indicators, and regular review and adjustment of treatment strategies should be carried out under the guidance of professional doctors. If no signs of disease control are observed within 3 months, doctors may recommend drug resistance evaluation or a change of treatment regimen. Therefore, patients should remain patient while taking the medication and closely cooperate with their doctors for regular follow-up and monitoring in order to optimize the treatment plan in a timely manner and improve the overall treatment success rate.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib